What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

To evaluate the efficacy of romiplostim in treating chemotherapy-induced thrombocytopenia (CIT) compared to placebo.

March 14, 2026New England Journal of Medicine1 citations

Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia

HAHanny Al-SamkariHarvard University CMCesar Gregorio MuñozInstituto de Investigación Sanitaria del Hospital Clínico San Carlos ÇGÇağlayan GeredeliIstinye University

Key Points

To evaluate the efficacy of romiplostim in treating chemotherapy-induced thrombocytopenia (CIT) compared to placebo.
Phase 3, placebo-controlled trial design
Participants with chemotherapy-induced thrombocytopenia
Comparison of treatment effects between romiplostim and placebo
Romiplostim showed efficacy in treating CIT compared to placebo

Abstract

In this phase 3, placebo-controlled trial, romiplostim was efficacious in treating CIT. (Funded by Amgen and the Biomedical Advanced Research and Development Authority; RECITE ClinicalTrials.gov number, NCT03362177.).

Ask AI

Helpful

Bookmark

View Full Paper